Background Black and Hispanic children with B-acute lymphoblastic leukemia (B-ALL) experience worse outcomes compared with their non-Hispanic white (NHW) counterparts. Immune-based approaches have begun to transform the therapeutic landscape in children with B-ALL. Recent studies identified several alterations in both innate and adaptive immune cells in children with B-ALL that may impact disease risk and outcome. However, the impact of racial/ethnic background on immune microenvironment is less studied, as children of minorities background have to date been severely under-represented in such studies.
Methods We performed high-dimensional analysis of bone marrow from 85 children with newly diagnosed B-ALL (Hispanic=29, black=18, NHW=38) using mass cytometry with 40 and 38-marker panels.
Results Race/ethnicity-associated differences were most prominent in the innate immune compartment. Hispanic patients had significantly increased proportion of distinct mature CD57 +T-bet+DR+ NK cells compared with other cohorts. These differences were most apparent within standard risk (SR) patients with Hispanic SR patients having greater numbers of CD57 +NK cells compared with other cohorts (43% vs 26% p=0.0049). Hispanic and Black children also had distinct alterations in myeloid cells, with a significant increase in a population of non-classical activated HLA-DR +CD16+myeloid cells, previously implicated in disease progression, compared with NHW counterparts. Racial background also correlated with altered expression of inhibitory checkpoint PD-L1 on myeloid cells.
Conclusion There are surprisingly substantial race/ethnicity-based differences in innate immune cells of children with newly diagnosed B-ALL. These differences urge the need to enhance accrual of children from minorities background in immunetherapy trials and may impact their outcome following such therapy.
- Tumor Microenvironment
- Hematologic Neoplasms
Data availability statement
De-identified data included in the manuscript will be available on request. NA.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
B-acute lymphoblastic leukemia (B-ALL) is a leading cause of cancer in children.1 Prior studies have shown that racial and ethnic background has strong association with survival of children with B-ALL, with worse outcomes in Hispanic (H) and black (B) children compared with their non-Hispanic white (NHW) counterparts.2 3 Several factors such as socioeconomic status, access to healthcare, treatment compliance, differences in tumor genetics, response to chemotherapy, genetic polymorphisms, and tumor genetics have been studied to understand these differences.4–12 However, there remains an unmet need to better understand the potential biological associations of racial/ethnic background and address these disparities.
Immune-based approaches have begun to transform the therapeutic landscape in childhood cancer including B-ALL.13 Recent studies have identified several alterations in the immune microenvironment of children with B-ALL.14 15 These differences include changes in both T cells (such as loss of naïve T cells and increase in terminal effector T cells), and innate immune cells, such as NK and myeloid cells.14 15 Some of these differences have been correlated with underlying disease risk and outcome in children with B-ALL.14 16 17 Properties of the immune microenvironment are also expected to impact outcomes with the emerging application of immune-based therapies in these patients. However, children from non-white background have been under-represented in prior analyses of immune microenvironment and clinical trials testing novel immune therapies in B-ALL.18 Whether race/ethnicity impacts the properties of immune microenvironment in these children may benefit from application of high-dimensional single-cell approaches.
Patients and samples
Diagnostic bone marrow specimens from children with B-ALL were provided by the Children’s Healthcare of Atlanta Pediatric Biorepository (patient characteristics in online supplemental table 1) under an institutional IRB-approved protocol. Written informed consent or patient assent and consent from the parent/legal guardian were obtained before collection of samples, in accordance with the Declaration of Helsinki. Clinical patient characteristics including race, ethnicity and NCI risk status were obtained from institutional database. An additional cohort of biospecimens (n=17) was obtained from Childrens’ Oncology Group (COG) biobank. Selection of samples analyzed in this study was based on availability of adequate diagnosis marrow in the institutional biorepository, collected between 2016 and 2019, focusing initially on all patients with racial/ethnic minority with available biospecimens and then inclusion of specimens from NHW children randomly selected and matched for patient characteristics including NCI risk status. The racial/ethnic diversity of the overall study population (20% black children) is representative of that seen in our clinics. The information available on specimens from COG biobank was limited to age, gender, race, NCI risk status and ETV-RUNX1 status.
Thawed mononuclear cells were stained with 40-marker and 38-marker panels using metal-conjugated antibodies at manufacturer-suggested concentrations (Fluidigm). For all newly conjugated antibodies, titrations were performed to determine the optimal concentration of antibody to be used for the studies. Details on the panels and specific antibodies/clones are provided in online supplemental table 2. Briefly, after staining for surface markers, the cells were fixed, permeabilized, and washed. After staining for intracellular markers, the cells were incubated with intercalation solution, mixed with EQ Four Element Calibration Beads, and acquired with a Helios mass cytometer. Cisplatin was used to stain non-viable cells and DNA content identified using iridium-labeled intercalator. To minimize batch effects, the same lot of antibody was used for all samples and samples from different groups (B, H, NHW) were thawed together and stained with the same antibody cocktail.
Data from mass cytometry were analyzed with CYTOBANK software using both manual gating as well as algorithms such as viSNE, based on Hispanic, NHW, and black categorization as well as NCI risk status (standard risk—SR, high risk—HR). After gating of singlet viable events with DNA intercalator uptake, individual clusters of cell types within individual patients were identified. Clusters were contrasted between patients to identify subsets of patients with concordant profiles of immune cells. Data were also pooled to create concatenated files from the marrow cells of patients in each of the racial/ethnic categories, using equal numbers of cells from each patient. Statistical analysis of mass cytometry data was performed using two-dimensional graphing and statistics software GraphPad Prism.
Results and discussion
Bone marrow mononuclear cells from 85 patients (H=29, NHW=38, B=18) with newly diagnosed B-ALL prior to initiation of chemotherapy were stained and characterized by mass cytometry (patient characteristics in online supplemental table 1). There were no significant differences in patient characteristics between the racial/ethnic groups. Tumor cells were gated out as CD45dimCD19+ CD10+to evaluate the non-tumor compartment in the marrow. There were no significant differences in the overall proportion of T cells, NK cells or myeloid cells between ethnic/racial groups (online supplemental figure 1).
Differences in NK cells
ViSNE clustering of NK cells (defined within the non-tumor compartment by CD45hiCD3-CD14-CD19-CD56+ events) identified three distinct NK populations (figure 1A). These populations were defined by their surface and cytosolic immune markers as (1) immature NK cells (CD56hiCD16-CD57-), (2) early cytotoxic NK cells (CD56dimCD16+CD57-Granzyme+), and (3) mature CD57+NK cells (CD56dimCD16+CD57+granzyme+) (figure 1B). The immature NK cells expressed higher levels of NKG2D and CD27 as previously described19 while CD57+NK cells expressed higher amounts of Tbet and HLADR in addition to granzymeB and lacked expression of CD27.19 Differences in NK cell subsets were most evident in the Hispanic group. Hispanic patients had higher proportions of CD57+ mature NK cells when compared with other groups, (42%±3% vs 33±2%; p=0.006) (figure 1C). These differences were most apparent within SR patients with Hispanic SR patients having greater numbers of CD57+NK cells compared with B and NHW SR patients (mean H SR 44±5% vs 25±2% p=0.001) (figure 1D–E).
Differences in myeloid cells
The myeloid cell compartment was defined within the non-tumor compartment by CD45hiCD3-CD56- cells that were positive for either CD11c or CD33. ViSNE clustering of myeloid cells identified five distinct clusters (termed M1-M5) based on patterns of cell surface markers (figure 2A). This included a CD14+CD16- classical monocyte population (M3), CD11c+DR low population(M4), CD33+C-kit+population (M2), CD11b/11c+CD15+population (M5) and a CD11c+CD16+DRhi inflammatory/non classical myeloid population (M1) (figure 2B). M1 myeloid population also expressed higher levels of PD-L1 as well as HLA-E (figure 2B). Further analysis showed that NHW SR patients have significantly lower proportions of CD16+DR+ myeloid cells (M1) compared with other groups (mean NHW SR 3±2% vs Others 17%±3% p=0.02) (figure 2C–D).
Differences in T cells
ViSNE analysis of T cells revealed four CD8 and two CD4 clusters progressing from CCR7/CD45RA+naïve cells to CD57+CD45RO-RA+terminally differentiated cells (online supplemental figure 2A, B). These subsets revealed expected changes in transcription factors and surface/cytosolic markers (online supplemental figure 2B), but in contrast to findings with innate immune cells, these clusters were comparable between racial/ethnic groups (online supplemental figure 2C).
Differences in immune checkpoints, transcription factors and co-stimulatory genes
Both CD4 +and CD8+T cells expressed PD-1, TIGIT as well as LAG-3 as major inhibitory immune checkpoints, while TIGIT was the dominant inhibitory checkpoint on NK cells and molecules in the TIGIT axis (CD112, CD155) were also prominent on myeloid cells (online supplemental figure 3). The expression of inhibitory checkpoints on CD4/CD8+T cells was comparable between racial/ethnic (R/E) cohorts (online supplemental figure 4). CD4/CD8+T cells also did not differ in terms of costimulatory molecules (CD27, CD28, 4-1BB) and key transcription factors (TCF1, T-bet, Eomes) (online supplemental figures 5 and 6). While checkpoints (LAG3, PD-1, TIGIT and DNAM-1) were comparably expressed on NK cells from different R/E cohorts (online supplemental figure 7A), NK cells from Hispanic patients expressed lower proportion of NKG2D, consistent with lower proportion of immature NK cells in this cohort19 (online supplemental figure 7B). Myeloid cells showed comparable expression of molecules on TIGIT axis and HLA-E in different R/E cohorts (online supplemental figure 8). Myeloid cells from SR-NHW cohort however had lower expression of PD-L1, consistent with prior data showing lower proportion of inflammatory myeloid cells in this cohort (online supplemental figure 9). Together, these data suggest that the prominent differences based on race/ethnicity are in the innate immune system.
These studies use a high-dimensional single cell proteomic analysis to identify several race/ethnicity-based differences in the immune microenvironment in children with B-ALL. Surprisingly, major race/ethnicity-based differences were found in the innate immune marrow non-tumor compartment. These differences are of interest as both NK and myeloid cells have been implicated in the immune-pathogenesis of B-ALL and therapies specifically targeting innate immunity are now entering the clinic.16 17 These differences may therefore not only contribute to poor disease-free survival in Hispanic and Black children, but also impact outcomes following treatment with emerging immune therapies.
In recent studies, alterations in NK cells have been linked to worse outcome in pediatric B-ALL.16 20 Single cell sequencing studies have also characterized altered transcriptional profiles in NK cells in B-ALL consistent with NK dysfunction.14 However, these initial studies were based on B-ALL samples from the Children’s Oncology Group tissue bank and samples from non-white racial/ethnic groups were underrepresented. The finding that Hispanic children had increased proportion of CD57 +mature NK cells is therefore of interest. This is a distinct subset of human NK cells with lower proliferative potential and decreased ability to secrete interferon gamma, but higher cytolytic function, that may expand in the setting of chronic viral infections.19 The mechanism underlying differences in NK differentiation in Hispanic children needs further study but may be related in part to differences in killer inhibitory receptor genotypes or environmental exposures in these children.21 In prior studies, changes in NK cells were more prominent in children with AML than in B-ALL.14 Therefore, it would also be of interest to evaluate if the race/ethnicity-associated differences in NK cells that we observed in B-ALL are also present in children with AML. Race/ethnicity related differences in NK biology may also have clear implications for the emerging application of NK-based therapies in leukemia.
These data have several implications for testing novel immune approaches to treat B-ALL in children. The finding that TIGIT and LAG-3 are prominently expressed by immune cells in children with B-ALL suggest that further studies to better understand the role that these clinically targetable immune checkpoint molecules play in the leukemic microenvironment should be explored. Combination studies involving TIGIT and LAG-3 blockade have recently shown promise in adult cancer and should be formally tested in pediatric leukemia.22 Our finding that black and Hispanic children have an increase in distinct populations of non-classical activated myeloid cells is also of interest, as this specific population was recently linked to leukemic progression in both patient specimens and preclinical models.17 In preclinical models, macrophage-targeted approaches led to improved outcome.17 Therefore, strategies targeting the myeloid compartment may be particularly useful in Hispanic or black children. NK-based immune therapies have already shown promise in adult cancers and are rapidly moving to the clinic.23 Our data suggest that racial/ethnic differences in NK biology may impact the translation of these strategies in the clinic, including in children.
Strengths of the current study are evaluation of specimens from patients with racially diverse representation obtained from a well-characterized biorepository and use of high-dimensional approaches validated in prior studies.14 24 25 Weaknesses include a relatively small sample size, although to our knowledge, this dataset represents one of the largest cohorts of non-white children analyzed at diagnosis of B-ALL with high-dimensional approaches. In prior studies, we have shown that risk status has a major impact on immune microenvironment.14 While the clinical features of different racial/ethnic cohorts were comparable, there could be yet unknown differences in cancer genetics in these cohorts. Nonetheless, these data need to be confirmed in another independent dataset, and as such should be viewed as hypothesis generating. Together, our novel finding is that there are surprisingly substantial differences in the innate immune compartment in Hispanic and black children with B-ALL. These findings implore the urgent and unmet need to include higher proportions of these children in current studies of immune microenvironment and emerging immune therapies, particularly those that specifically target innate immunity.
Data availability statement
De-identified data included in the manuscript will be available on request. NA.
Patient consent for publication
Diagnostic bone marrow specimens from children with B-ALL were provided by the Children’s Healthcare of Atlanta Pediatric Biorepository under an institutional IRB-approved protocol. Written informed consent or patient assent and consent from the parent/legal guardian were obtained before collection of samples, in accordance with the Declaration of Helsinki.
We would like to acknowledge the Aflac Cancer and Blood Disorders and Cancer Center Pediatric Leukemia/Lymphoma Pediatric Biorepository for providing the samples for these studies and Allison Carr in Dr Madhav Dhodapkar’s lab for technical assistance with antibody conjugations. Aflac pilot project funds to HSS and KMD were used to support some of these studies. We would also like to acknowledge the Winship Immune Monitoring Resource for single cell mass cytometry (supported by P30CA138292 to Winship shared resources).
Contributors JRG designed and performed experiments, analyzed data and wrote the manuscript, RR and DBD performed experiments and analyzed data, HSS and SMC helped design study, collected patient material and edited the manuscript, DBD collected patient material and edited manuscript, KD designed and supervised the study, analyzed data and wrote the manuscript.
Funding This study was funded by Cancer Center and Aflac (P30CA138292).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.